Oncotarget

Research Papers:

Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

Ping Liang, Hongming Shi, Weiguo Zhu, Qunfeng Gui, Ya Xu, Jianfeng Meng, Xiaoyuan Guo, Zhuang Gong and Huaqun Chen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:7533-7539. https://doi.org/10.18632/oncotarget.13503

Metrics: PDF 2167 views  |   HTML 2174 views  |   ?  


Abstract

Ping Liang1, Hongming Shi1, Weiguo Zhu1, Qunfeng Gui1, Ya Xu1, Jianfeng Meng1, Xiaoyuan Guo2, Zhuang Gong3, Huaqun Chen1

1Department of Neurology, Yancheng Hospital Affiliated to Southeast University, Yancheng, 224001, China

2Department of Neurology, Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China

3Department of Nephrology, The First People’s Hospital of Yancheng Affiliated to Nantong University, Yancheng, 224001, China

Correspondence to:

Huaqun Chen, email: drliangping@126.com

Keywords: silver nanoparticles (AgNPs), glioma cells, temozolomide (TMZ), chemotherapy

Received: August 20, 2016     Accepted: November 07, 2016     Published: November 22, 2016

ABSTRACT

Glioblastoma multiforme (GBM) continues to be associated with a dismal prognosis despite aggressive treatment. Significant efforts are being made to develop new nanotechnology-based therapeutic and diagnostic agents. Nanoparticles can act directly on cancer cells or as drug carriers to enhance the cancer therapeutic effect. In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells. AgNPs were synthesized in the sodium citrate system and the mean size were 26 nm in diameter. The AgNP particles showed dose-dependent cytotoxicity on U251 cells. They also showed the ability to enhance the drug-sensitivity of TMZ on U251 cells. Our results revealed that AgNPs could have a potential application in enhancing chemotherapy for glioma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13503